FOOD AND DRUG ADMINISTRATION ISSUES NOTICE: BIOSIMILAR USER FEE ACT III REGULATORY SCIENCE PROGRAM INTERIM PUBLIC MEETING; PUBLIC MEETING; INTERIM REPORT; AVAILABILITY; REQUEST FOR COMMENTS

WASHINGTON, Aug. 15 -- Food and Drug Administration has issued a notice called: Biosimilar User Fee Act III Regulatory Science Program Interim Public Meeting; Public Meeting; Interim Report; Availability; Request for Comments.

The notice was published in the Federal Register on Aug. 15 by Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs.

Summary: The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Biosimilar User Fee Act (BsUFA) III Regulatory Science Program Interim Public Meeting" and the availability of the report entitled "BsUFA III Regulatory Science Pilot Program Interim Report." The purpose of the public meeting is to review the progre...